Boehringer Fails to Inform Public of Mirapex Heart Failure Risk

According to a recent report, drugmaker Boehringer Ingelheim failed to completely inform the public about information that suggested the dopamine agonist Mirapex (pramipexole) was linked to an increased risk of heart failure.

The drug, which was originally developed to treat Parkinson’s disease, is now used to treat Restless Legs Syndrome as well.

Even though heart failure was an adverse event that was found during clinical trials with the drug and is noted on its label, a more definite link was not established until recently, according to Forbes. Ed Silverman from Pharmalot says Boehringer seems to have been aware of the stronger association beforehand but did nothing to publish the new information.

Mirapex has also been linked to gambling addictions in some people.

If you or a loved one has been harmed by a dangerous drug, contact Sokolove Law for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you. Call us today at (800)-561-7154.

Tags:

About Us

Sokolove Law, LLC is the nation’s largest marketer of legal services that help people obtain access to the civil justice system while ensuring they receive superior quality legal representation. With over 30 years of service, Sokolove Law has helped thousands of injured parties obtain the compensation they deserve from their legal claim such as mesothelioma, cerebral palsy, nursing home abuse, dangerous drugs, disability insurance denial, and medical malpractice cases.

Subscribe

Quick facts

Boehringer Fails to Inform Public of Mirapex Heart Failure Risk
Tweet this